Source comparison
Peptides for TBI Recovery: Mechanism Comparison
Cerebrolysin BDNF/NGF mimetic, anti-apoptotic (Bcl-2 upregulation) 10–30 mL IV daily × 10–21 days Acute (0–72 hrs) Multiple RCTs, meta-analysis shows 18% mortality reduction P21 CNTF-derived, inhibits neuronal apoptosis 500 mcg SC daily × 7–14 days Acute Precl
This comparison does not assign a generated winner or score.
- Cerebrolysin
- BDNF/NGF mimetic, anti-apoptotic (Bcl-2 upregulation)
- 10–30 mL IV daily × 10–21 days
- Acute (0–72 hrs)
- Multiple RCTs, meta-analysis shows 18% mortality reduction
- P21
- CNTF-derived, inhibits neuronal apoptosis
- 500 mcg SC daily × 7–14 days
- Acute
- Preclinical (animal models), early human trials
- Dihexa
- HGF/c-Met potentiation, synaptogenesis
- 2–5 mg SC 2–3×/week × 4–8 weeks
- Subacute (72 hrs–4 weeks)
- Preclinical, anecdotal research reports
- Thymalin
- T-cell regulation, anti-inflammatory
- 10 mg SC every other day × 20 doses
- Subacute
- Immunology literature, not TBI-specific
- MK-677
- GH/IGF-1 secretagogue, hippocampal neurogenesis
- 10–25 mg oral daily
- Chronic (>4 weeks)
- Human trials in elderly, sleep/cognition improvements